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This multicentre, randomised, controlled cross-over trial was designed to investigate the effect of intra-
uterine slow-release insemination (SRI) on pregnancy rates in women with confirmed infertility or the 
need for semen donation who were eligible for standard bolus intra-uterine insemination (iUi). Data for 
a total of 182 women were analysed after randomisation to receive IUI (n = 96) or SRI (n = 86) first. The 
primary outcome was serological pregnancy defined by a positive beta human chorionic gonadotropin 
test, two weeks after insemination. Patients who did not conceive after the first cycle switched to the 
alternative technique for the second cycle: 44 women switched to IUI and 58 switched to SRI. In total, 
there were 284 treatment cycles (IUI: n = 140; SRI: n = 144). Pregnancy rates following SRI and IUI 
were 13.2% and 10.0%, respectively, which was not statistically significant (p = 0.202). A statistically 
significant difference in pregnancy rates for SRI versus IUI was detected in women aged under 35 years. 
In this subgroup, the pregnancy rate with SRI was 17% compared to 7% with IUI (relative risk 2.33; 
p = 0.032) across both cycles. These results support the hypothesis that the pregnancy rate might be 
improved with SRI compared to standard bolus IUI, especially in women aged under 35 years.
Globally, 10–15% of couples of reproductive age are affected by infertility1. Following diagnosis of infertility, and 
evaluation of its causes, couples can be provided with information about their likelihood of achieving a spontane-
ous pregnancy, and their chance of pregnancy after different treatment options. Intrauterine insemination (IUI) 
is often the first step in infertility treatment for couples with unexplained infertility, low-grade endometriosis, 
sexual function disorders and low-grade male subfertility2. Pregnancy rates following artificial insemination are 
low3 and depend on several factors, including: age; reason for sub-fertility or infertility; absence/presence and 
type of ovarian stimulation and timing of insemination3,4 as well as the number of inseminated motile sperm5,6.
A large retrospective cohort study, covering more than 15,000 IUI-cycles, reported a mean pregnancy rate 
of 5.6% per cycle, and cumulative ongoing pregnancy rates after the third, seventh and ninth cycles of 18%, 
30% and 41%, respectively7,8. These data clearly show the importance of developing new strategies for improving 
pregnancy rates after IUI. Most studies that have investigated methods for improving pregnancy rates after IUI 
have focused on the choice of clomiphene citrate (CC; now being superseded by letrozole) or recombinant follicle 
stimulating hormone (rFSH), with or without the use of gonadotropin-releasing hormone (GnRH) antagonists 
to stimulate ovulation9–13. Some studies dealt with the question of immobilisation versus immediate mobilisation 
following the insemination procedure - as immediate mobilisation might cause leakage of spermatozoa out of the 
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uterus - and provided conflicting results14–16. However, only a few studies have dealt with changes to the IUI tech-
nique itself, or have questioned the application method5. One alternative to IUI is intratubal insemination (ITI), 
also known as fallopian tube sperm perfusion (FSP). This technique differs from IUI in that a higher volume of 
prepared semen is used (4 ml compared with ≤0.5 ml) and is introduced directly into the fallopian tubes17. The 
hypothesis is that the presence of a higher sperm density in the fallopian tubes at the time of ovulation is more 
likely to result in pregnancy; however, available evidence suggests that there is no clear benefit for ITI/FSP over 
IUI18–20. Another modified IUI application technique is slow release insemination (SRI), which was first described 
in 199221. The authors hypothesised that a persistent low concentration of spermatozoa might prolong the period 
of potential fertilisation and thereby mimic physiological sperm transportation from the cervix to the fallopian 
tube. We have recently published data from two pilot randomised, controlled cross-over studies that indicate a 
statistically significant advantage of SRI over conventional bolus IUI22. The present, larger, multicentre trial was 
performed to clarify the effect of intra-uterine SRI on pregnancy rates in women designated for standard bolus 
IUI.
Materials and Methods
Study design and patient population. This multicentre, randomised, controlled cross-over trial was con-
ducted in women with infertility and/or the need for semen donation who were eligible for IUI in 11 fertility cen-
tres across Europe. As already stated in a prior pilot study22, the cross-over design was chosen because it has been 
shown to give results comparable to those from studies with a parallel design, and, thus, to be a valid approach 
for infertility trials23,24.
Oral and written informed consent was obtained from all participants. The study was approved by the main 
ethics committee of the Medical University of Vienna (EK 1227/2012) and by all other local ethics committees. It 
was conducted in accordance with the Declaration of Helsinki and was registered in the Current Controlled Trials 
Register (registration number NCT02315040, 19/10/2014).
Patients were recruited between October 2012 and June 2017. Women were included if they fulfilled all of 
the following criteria:22 (i) primary or secondary infertility, defined as a couple’s failure to conceive after 12 
months of attempting conception; (ii) age 20–40 years; (iii) tubal patency as diagnosed by hysterosalpingography, 
hystero-contrast-sonography (hycosy) or dye test with a maximum time interval between tubal testing and the 
woman’s enrolment into the study of 12 months; (iv) since the total motile sperm count is a major factor which 
influences pregnancy changes after IUI25, a minimum of 10 million motile sperm cells/ millilitre (mio/ml) after 
preparation; (v) infertility due to anovulation and/or endometriosis and/or the need for semen donation and/or 
unexplained infertility. In this context, unexplained infertility is defined as the absence of a definable reason for 
a couple’s failure to conceive after 12 months of attempting conception despite a detailed evaluation of ovulation, 
tubal and uterine abnormalities and male infertility factors.
Patients with uterine abnormalities, such as a septate uterus, were excluded.
A computerised randomisation programme was used initially to assign women to either the standard bolus 
IUI treatment or the SRI method. Women who failed to conceive in this first course of treatment were then allo-
cated to the alternative method for the second treatment.
The primary outcome parameter was serological pregnancy defined as a positive beta human chorionic gon-
adotropin (hCG) test (in urinary or blood samples) two weeks after insemination. Information on the patient’s 
age, gravidity, cause of infertility, reproductive and concomitant medications was collected along with informa-
tion on her partner’s age, sperm motility, sperm count and percentage of normal/abnormal sperm according to 
the analysis on the day of the SRI or IUI procedure. Details of any adverse events (AEs) were also recorded.
follicle monitoring and ovarian stimulation. In unstimulated cycles transvaginal sonography for folli-
cular monitoring was performed depending on the anticipated ovulation between day 10 and14 of the menstrual 
cycle and was continued until a follicle size over 18 mm was reached. 35–38 hours after endogenous LH-surge or 
ovulation induction with human chorionic gonadotropin (hCG) 5,000 or 10,000IU intramuscularly (Pregnyl®, 
Merck Serono; Brevactid®, Ferring Pharmaceuticals; Choragon®, Ferring Pharmaceuticals) or chorionic gon-
adotropin alpha 250 or 500 μg subcutaneously (Ovitrelle®, Merck Serono) the insemination (IUI/SRI) was 
performed.
Controlled ovarian stimulation was performed either with human menopausal gonadotropin (Menopur®, 
Ferring Pharmaceuticals) or Follitropin alpha/beta (Gonal F®, Merck Serono; Puregon®, Merck Sharp & Drohne) 
or combined Follitropin alpha/Lutropin alpha (Pergoveris®, Merck Serono) 75 IU subcutaneously starting from 
day 3–5 of the menstrual cycle or with clomiphene citrate 50 mg from day 5–9. Follicular monitoring was started 
on day 10 until a follicle size over 18 mm was recorded. 35–38 hours after ovulation induction with hCG 5,000 or 
10,000IU intramuscularly (Pregnyl®, Merck Serono; Brevactid®, Ferring Pharmaceuticals; Choragon®, Ferring 
Pharmaceuticals) or chorionic gonadotropin alpha 250 or 500 μg subcutaneously (Ovitrelle®, Merck Serono) the 
insemination (IUI/SRI) was performed. Cycles were cancelled if more than 2 follicles over 16 mm were present. In 
stimulated cycles women received either vaginal progesterone 200 mg once daily or dydrogesterone 10 mg twice 
daily for 14 days.
Sperm preparation method. The sperm preparation method was performed according to the World 
Health Organisation laboratory manual for the examination and processing of human semen (2010) either with 
density gradient preparation (n = 144/284) or swim up procedure (n = 140/284) from good quality samples using 
commercially available media (GM501 SpermAir - Gynemed GmbH & Co. KG, Lensahn, Germany; Gynemed 
Gradient 45%/90% - Gynemed GmbH & Co. KG, Lensahn, Germany; Origio sperm preparation medium – 
Origio, Måløv, Denmark).
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Density gradient preparation: Application of each 1–1.5 ml of 45% and 90% gradient on the bottom of a 
conical test tube. Centrifugation of the test tube between 500–1,500 rpm, depending on sperm-counts, for 
20–30 minutes (24–210xg). Aspiration of the pellet and resuspension with 2–5 ml of buffer. Centrifugation at 
1,500–2,000 rpm for 10 minutes (210–380xg). Evaluation of sperm concentration and progressive motility.
Swim up procedure: Transfer of 1.5 ml of buffer into a test tube at a temperature of 25–36 °C. Injection of 
0.5 ml of the sperm sample with a sterile 1 ml syringe in the bottom of the test tube. Incubation of the test tube for 
15 to 30 minutes at a temperature of 35–36 °C.
Lift of the supernatant with motile sperm cells and transfer to a sterile test tube. Evaluation of sperm concen-
tration and progressive motility.
Standard bolus iUi technique. The standard bolus IUI is accomplished as described elsewhere22 with a 
polyethylene insemination catheter (5 French, 28 cm). Before performing the IUI, the catheter is joined to a 1 ml 
tuberculin syringe containing laboratory-prepared sperm. This is connected to the insemination catheter, which 
is inserted into the uterine cavity. After the injection of sperm and removal of the catheter, the patient is able to 
leave the clinic.
SRi technique. In this study, the EVIE device was used for women undergoing SRI. The device consists of a 
disposable EVIE syringe pump (Fertiligent, Ra’anana, Israel), a 3 ml sterile syringe (Becton Dickinson; Franklin 
Lakes, NJ) and a customised HSG catheter with inflatable anchor balloon at the tip (Catheter Research Inc; 
Indianapolis, IN). The disposable pump (Fig. 1) is a mechanical device in which a spring pushes the syringe 
plunger with a patented spring restriction mechanism; this allows it to keep running during the four-hour deliv-
ery period. Prepared sperm solution is held in a sterile, sperm-compatible syringe in the chamber of the EVIE 
device before being delivered through the catheter over four hours. The insertion of the catheter into the uterus 
is performed as for standard IUI. In contrast to the standard IUI procedure, however, after positioning the EVIE 
catheter into the uterine cavity, it is anchored in the uterus by using normal saline solution (1 ml) to fill the bal-
loon positioned at the end of the catheter. The pump is strapped to the patient’s thigh and the device is activated 
by pressing button marked number 1. The patient is able to remain mobile (completely ambulatory) during the 
four-hour insemination procedure. There is no need for her to rest, and she may leave the clinic to go home. Once 
four hours has elapsed, button number 2 is pressed. This completes the procedure by flushing any remaining 
sperm in the syringe into the uterus. The patient removes the catheter herself by opening the white stopcock to 
empty the balloon before withdrawing the catheter. The entire device is then discarded.
Sample size calculation. The a priori sample size for the study was calculated using a minimum clinically 
significant effect defined as a relative risk of 2.0 in favour of SRI and an estimated pregnancy rate for IUI for 
women aged <40 years of 14.3% (which was observed in an unpublished pilot data set). Using these estimates, 
a minimum sample size of 137 treatment cycles per group (treating each insemination as a separate case) was 
required for a superiority trial with a power of 90% and a significance level of 0.05.
Statistical analysis. Data for a maximum of two cycles (one SRI and one IUI per woman) only were ana-
lysed. Data from patients who withdrew due to adverse effects or device failure, or who failed to comply with the 
protocol, were treated as missing. Because of the nature of the study design, each treatment (rather than each 
person) was considered as an independent case.
For numerical parameters, variables are summarised as either mean ± standard deviation (SD) or median 
with inter-quartile range (IQR) depending on the data distribution. For categorical parameters, data are presented 
as frequencies and percentages.
Chi-squared or Fishers’ exact tests were used to compare categorical variables between the two groups and 
independent-samples median tests were used to compare non-parametric numerical variables. One-tailed z-tests 
were used to test for superiority (i.e. relative risk [RR] of >1) of the pregnancy rate of SRI over IUI.
Figure 1. Schematic Illustration of the EVIE Slow Release Insemination Pump. (Figure by courtesy of 
Fertiligent Ltd.).
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IBM SPSS 22.0 (SPSS Inc; Chicago, IL) was used for statistical analysis. P-values of less than 0.05 were consid-
ered statistically significant.
ethical approval. The study was approved by the main ethics committee of the Medical University of Vienna 
(EK 1227/2012) and by all other local ethics committees. All procedures performed in studies involving human 
participants were in accordance with the ethical standards of the institutional and/or national research committee 
and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was 
registered in the Current Controlled Trials Register (registration number NCT02315040).
informed consent. Oral and written informed consent was obtained from all participants.
Results
A total of 183 women were randomised into the two treatment arms (Fig. 1): 96 (52.5%) women received standard 
IUI treatment first and 87 (47.5%) women received SRI treatment first. The EVIE device did not fully actuate in 
one patient assigned to the SRI group: she received a bolus at the end of the 4-hour administration period and 
her data were excluded from the analysis. Characteristics for analysed patients and their partners are shown in 
Table 1: there were no significant differences between the two groups. The median age of women participating 
in the study was 33 years (IQR 30–36 years). Donor sperm was used in 37 treatments for 23 women (13%). 102 
women underwent a second treatment cycle (IUI: n = 44; SRI: n = 58; Fig. 2). In total, there were 284 treatment 
cycles (IUI: n = 140; SRI: n = 144).
The observed overall serological pregnancy rate for SRI was 13.2%, compared to 10.0% for IUI (relative risk 
[RR] = 1.32); however, this difference was not statistically significant (95% confidence interval [CI] 0.69–2.53; 
p = 0.202).
Effect of age on pregnancy rates. In total, 172 inseminations were performed in patients aged under 35 
years (IUI: n = 83; SRI: n = 89). For all women aged under 35 years undergoing SRI, the observed RR for preg-
nancy was 2.33, with 16.9% of the SRI procedures resulting in pregnancy (n = 15) compared to 7.2% of the IUI 
procedures (n = 6). This difference was statistically significant (p = 0.032). There were no significant differences 
IUI procedures 
(n = 140)
SRI procedures 
(n = 144) p-valueb
Female age, years* 33 (30-36) 33 (30-36) 0.840
Body Mass Index (kg/m2)* 22 (20-24) 22 (20-24) 0.899
Previous pregnancies
   0# 81 (58%) 91 (63%) 0.511
   1# 47 (33%) 39 (27%)
   >1# 12 (9%) 13 (9%)
Cause of infertility
   Endometriosis# 10 (7%) 11 (7%) 0.672
   Anovulation# 22 (16%) 27 (19%)
   Unexplained infertility# 108 (77%) 105 (73%)
   Donor Insemination# 19 (14%) 18 (13%) 0.789
Reproductive Medication‡
   Clomiphene 48 49 0.963
   Gonadotropins 89 90 0.852
   Progesterone 33 33 0.896
Concomitant Medication
   Levothyroxine 9 8 0.757
   Otherc 4 6 0.549
   Male age, years* 36 (33–40) 35.5 (32–39) 0.468
Semen analysisa
   Concentration (mio/ml)* 45 (17-77) 40 (15-77) 0.468
   Motility (%)* 55 (45-75) 54 (45-73) 0.519
   Normal morphology (%)* 19 (6-75) 12 (5-80) 0.394
Treatment cycle
   1# 96 86 0.120
   2# 44 58
Table 1. Baseline characteristics of all couples undergoing IUI and SRI procedures. IUI, intrauterine insemination; 
SRI, slow-release insemination. Data are presented as *median (interquartile range) or #n (%). ‡Reproductive 
medication – data presented as cumulative reproductive medication, multiple entries possible. aSemen analysis – 
after preparation. bMedian test (numerical data); chi-squared/Fishers’ exact test (categorical data).
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with respect to female and male characteristics for patients aged under 35 years in the IUI and SRI subgroups 
(Table 2). Total pregnancy rates following SRI and IUI are provided in Table 3.
Safety. There were no significant differences in the proportions of women reporting adverse events with the 
SRI procedure compared to the IUI procedure (7/144 vs. 1/140, p = 0.071) (Table 4). Two patients who experi-
enced pain during catheter insertion, and one patient with syncope did not proceed with SRI treatment, but all 
other patients who reported adverse events did. No serious adverse events were recorded. With respect to preg-
nancy related complications there were 3 ectopic pregnancies reported following SRI and none following IUI. 
However, this difference was not statistically significant (p = 0.248) (Table 4).
Discussion
In this paper we report the results of the largest, randomised, controlled trial of a modified IUI technique, which 
was first described in 199221.
In standard IUI, a bolus of highly-concentrated spermatozoa is delivered directly into the uterine cavity near 
to the fallopian tubes to increase the density of capacitated spermatozoa near the presumed oocyte, thereby opti-
mising the chance for pregnancy17. However, a proportion of the spermatozoa are expelled through the fallopian 
tubes into the peritoneal fluid26,27 when a volume of 0.5 ml is used. This means that there is scope for improvement 
in this technique.
The concept underlying SRI is that a smaller number of spermatozoa continuously released into the uterus 
over an extended period of time will prolong the period of potential fertilisation, more closely mimicking physi-
ological continuous sperm transportation into the fallopian tubes22. It could be hypothesised that this prolonged 
usage of the insemination balloon catheter in SRI also improves the transport of spermatozoa along the fallopian 
tubes by stimulating local prostaglandin production as a result of the pressure on the endocervix. However data 
about this hypothesis is very weak. Moreover, there is literature postulating a negative effect of inseminating too 
much sperm cells all at once5,28. These papers place this in the context of excessive reactive oxygen species (ROS) 
formation and multiple fertilization of the oocyte if too many sperm cells are present in the uterus or oviduct. 
Therefore slow release insemination with its duration of 4 hours and only inseminating few spermatozoa per 
minute could avoid this effect.
Muharib et al. were the first to report an improvement of pregnancy rates using this technique compared to 
the standard bolus technique21. A re-analysis of their data indicated that this difference failed to reach statisti-
cal significance (p = 0.057)22. A subsequent meta-analysis of data from the Muharib et al. study and two pilot 
studies demonstrated that SRI was statistically significantly more effective than IUI (RR 2.64; 95% CI 1.04–6.74; 
p = 0.02)22.
This randomised, controlled, multicentre trial demonstrated an overall numerically – but not statistically sig-
nificant – higher pregnancy rate with the SRI procedure. In the subgroup of women aged under 35 years, preg-
nancy rates were significantly higher with the SRI procedure. Of note, women under 35 years of age are routinely 
referred for IUI, as falling pregnancy rates in older women might lead to earlier IVF treatment.
It is well known that pregnancy rates decrease with female age, whether or not artificial insemination is 
required29–31. In their much larger study in patients undergoing IUI, Schorsch et al. reported statistically sig-
nificantly higher pregnancy rates for women below the age of 25 compared to women aged 35 years and over 
(p < 0.001), and they concluded that age was an important factor in achieving pregnancy after IUI31. The impact 
of male and female age on pregnancy rates after SRI needs to be analysed in further studies.
To exclude a bias on pregnancy rates by different stimulation methods within the treatment groups, we doc-
umented the method of stimulation (Tables 1 and 2). While generally there was no difference in the use of CC, 
rFSH or progesterone within the groups, an exceptionally high pregnancy rate in patients aged less than 35 years 
Figure 2. Flow chart showing the initial randomisation to IUI or SRI, pregnancy rates and numbers of patients 
crossing over to the alternate procedure. (IUI, intrauterine insemination; SRI, slow-release insemination).
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IUI procedures 
(n = 83)
SRI procedures 
(n = 89) p-valueb
Female age, years* 31 (28–33) 30 (28–33) 0.864
Body Mass Index (kg/m2)* 21 (20–24) 22 (20–24) >0.999
Previous pregnancies
   0# 51 (62%) 62 (70%) 0.498
   1# 26 (31%) 21 (23%)
   >1# 6 (7%) 6 (7%)
Cause of infertility
   Endometriosis# 4 (5%) 4 (4%) 0.490
   Anovulation# 16 (19%) 24 (27%)
   Unexplained infertility# 63 (76%) 61 (69%)
   Donor Insemination# 11 (13%) 9 (10%) 0.521
Reproductive Medication‡
   Clomiphene 26 29 0.860
   Gonadotropins 54 59 0.865
   Progesterone 22 24 0.946
Concomitant Medication
   Levothyroxine 4 6 0.590
   Otherc 2 3 >0.999
Male age, years* 34 (30–37) 34 (29–37) 0.759
Semen analysisa
   Concentration (mio/ml)* 45 (22–78) 40 (15–76) 0.398
   Motility (%)* 54 (43–76) 52 (43–69) 0.291
   Normal morphology (%)* 17 (7–70) 10 (5–72) 0.263
Treatment cycle
   1# 55 57 0.760
   2# 28 32
Table 2. Baseline characteristics of couples undergoing IUI and SRI procedures where the woman was aged 
under 35 years. IUI, intrauterine insemination; SRI, slow-release insemination. Data are presented as *median 
(interquartile range) or #n (%). ‡Reproductive medication – data presented as cumulative reproductive 
medication, multiple entries possible. aSemen analysis – after preparation. bMedian test (numerical data); chi-
squared/Fishers’ exact test (categorical data).
Insemination method Pregnancy rate (%)
All women 11.6
SRI 13.2
IUI 10.0
Women <35 years 12.2
SRI 16.9*
IUI 7.2
Table 3. Pregnancy rates following slow release insemination and intrauterine insemination. IUI, intrauterine 
insemination; SRI, slow-release insemination. *Statistically significant.
Event
IUI procedure 
(n = 140)
SRI procedure 
(n = 144)
Post-interventional spotting 1 3
Pain during catheter insertion 0 2
Pain and cramps during 
procedure 0 1
Vasovagal syncope 0 1
Multiple pregnancies 0 0
Ectopic pregnancies 0 3
Table 4. Adverse events. IUI, intrauterine insemination; SRI, slow-release insemination.
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using CC and undergoing SRI was found (24,1%). Overall, however, no significant differences in the use of med-
ications could be discovered in the treatment of women who became pregnant after SRI or IUI.
Values for absolute pregnancy rates with IUI differ widely in the literature; however, we could not find any 
other modification of the method or medication for IUI that had as strong an effect on pregnancy rates as SRI. 
This observation shows the potential benefit of SRI. IUI is a cost-effective method for increasing pregnancy rates 
in couples with unexplained infertility, which is why IUI is often chosen as first-line therapy in these patients32. 
One could speculate that an improvement in success rates with SRI might further reduce the number of referrals 
for more expensive assisted reproductive technology, and hence reduce the overall costs of infertility treatment; 
however, carefully designed clinical trials would be required to prove this.
We are aware that the cross-over design might be seen as a major limitation of this study. As already stated 
cross-over studies with repeated interventions on the same patient are not traditionally recommended for tri-
als where a successful outcome will have a permanent serial effect (in this case, pregnancy) that results in the 
withdrawal of the patient from the second arm of the trial22. Pregnancy after the first treatment unbalances the 
research design and introduces a period effect. For this reason, some authors reject the utilisation of this study 
design in infertility trials33,34; however, others claim that it is an efficient and pragmatic design, particularly as only 
one cycle of each treatment is given to each woman23,24. To show this effect in our study, we evaluated the data 
from the first treatment course in patients aged under 35 years.
During the first cycle, 112 inseminations were performed in these patients; of these, 55 were randomised to 
the IUI procedure, and 57 to SRI. 5.5% and 14%, respectively, resulted in pregnancy (RR = 2.57). This difference 
was not statistically significant (95% CI for RR 0.72–9.20; p = 0.073); however, this can be explained by a lack of 
statistical power due to the small number of treatments (actual power = 46%). Cross-sectional studies have been 
shown to be a valid approach in infertility research:23 Takada et al. recently reported that the crossover design 
has the highest power and the smallest bias24. These authors recommended using a combination of a cross-over 
design and the Mantel-Haenszel method for two-period, two-treatment clinical trials with irreversible endpoints.
The mentioned considerations about sample size must also be included into the discussion about study limita-
tions. The power calculation was done for the whole study population and not for women aged <35 years. Thus, 
the population size in the latter group is small and the analysis of this subgroup seems vulnerable to chance. This 
issue could have been solved by including women of younger age only which has not been the case.
The lack of information on previous infertility treatments and the use of donor sperm may additionally be 
seen as another limitation of the study. Moreover, two different types of sperm preparation methods may intro-
duce bias. There were approximately equal numbers of IUI and SRI (19 IUI, 18 SRI) performed with donor sperm. 
This study, however, mainly included couples with unexplained infertility and not subfertile men, as sperm qual-
ity inclusion criteria were very strict. In this context we have to state that the sperm volume was not evaluated 
which we consider as minor study limitation.
The wide use of CC in the present study also must be discussed critically, as we are aware that this might be consid-
ered controversial. In accordance with the guidance from the Practice Group of the American Society for Reproductive 
Medicine, the relatively high rate of anovulation in both groups was addressed by administering CC35. The guidance 
notes that CC used in combination with IUI in cases of unexplained infertility seems to be beneficial. Up to three cycles 
is considered a common therapeutic regimen before progressing to more aggressive therapies. Last not least, despite 
the small sample size to achieve, the study period was quite long. Empirically, this was due to the fact that women did 
not accept IUI well and often opted for IVF instead. Moreover, the study was performed in 11 different centres around 
Europe which might have introduced some kind of unknown bias. However, since all centres performed IUI and SRI 
with similar frequency, we believe that this circumstance was of minor relevance. Interestingly, the only ectopic preg-
nancies reported in this study were following the SRI procedure. Althoug this difference was not statistically significant, 
the population size of this group is too small to draw any conclusions concerning safety regarding this point.
conclusion
In conclusion, these data lend support to the hypothesis that the pregnancy rate might be improved by using SRI 
rather than IUI, especially in women aged less than 35 years. Due to the above-mentioned study limitations, this 
trial should be seen as an additional pilot study which can also serve as a basis for future trials. Thus, additional, 
larger, clinical trials are required to fully prove the hypothesis of SRI’s superiority, especially if an economic ben-
efit of SRI is also to be demonstrated, but also to evaluate potential adverse effects of this procedure with respect 
to the occurrence of ectopic pregnancies.
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